Get the Stockscreener App
8.85
0.90%
-0.08
After Hours:
8.85
Prothena Corporation Plc stock is traded at $8.85, with a volume of 333.92K.
It is down -0.90% in the last 24 hours and down -0.67% over the past month.
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.
See More
Previous Close:
$8.93
Open:
$8.93
24h Volume:
333.92K
Relative Volume:
0.57
Market Cap:
$476.40M
Revenue:
$217.25M
Net Income/Loss:
$-50.92M
P/E Ratio:
-8.85
EPS:
-1
Net Cash Flow:
$-100.85M
1W Performance:
+5.99%
1M Performance:
-0.67%
6M Performance:
+17.37%
1Y Performance:
-35.96%
1-Day Range:
$8.72
$9.04
1-Week Range:
$8.56
$9.12
52-Week Range:
$4.32
$16.66
Prothena Corporation Plc Stock (PRTA) Company Profile
Name
Prothena Corporation Plc
Sector
Industry
Phone
011-353-1-236-2500
Address
77 SIR JOHN ROGERSON'S QUAY, BLOCK C, DUBLIN 2
Compare PRTA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PRTA
Prothena Corporation Plc
|
8.85 | 480.70M | 217.25M | -50.92M | -100.85M | -1.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Prothena Corporation Plc Stock (PRTA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-28-25 | Downgrade | BofA Securities | Neutral → Underperform |
| May-27-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| May-27-25 | Downgrade | Jefferies | Buy → Hold |
| May-27-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-20-24 | Initiated | Chardan Capital Markets | Buy |
| Jan-30-24 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Apr-24-23 | Initiated | SVB Securities | Outperform |
| Jan-27-23 | Initiated | Piper Sandler | Overweight |
| Nov-04-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Sep-28-22 | Upgrade | BofA Securities | Neutral → Buy |
| Nov-19-21 | Initiated | JMP Securities | Mkt Outperform |
| Jun-18-21 | Upgrade | BofA Securities | Underperform → Neutral |
| Jun-08-21 | Reiterated | Oppenheimer | Outperform |
| May-26-21 | Initiated | Citigroup | Buy |
| Feb-26-21 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Feb-12-21 | Upgrade | Jefferies | Hold → Buy |
| Feb-02-21 | Upgrade | BTIG Research | Neutral → Buy |
| Dec-07-20 | Initiated | H.C. Wainwright | Buy |
| Jul-09-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-19-19 | Upgrade | Evercore ISI | In-line → Outperform |
| May-21-18 | Downgrade | Barclays | Equal Weight → Underweight |
| Apr-23-18 | Downgrade | Jefferies | Buy → Hold |
| Apr-05-18 | Reiterated | Barclays | Overweight |
| Nov-20-17 | Downgrade | Wedbush | Outperform → Neutral |
| Sep-29-17 | Reiterated | BTIG Research | Buy |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Aug-17-17 | Initiated | Evercore ISI | Outperform |
| Jul-11-17 | Initiated | Jefferies | Buy |
| Apr-12-17 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-12-17 | Initiated | Piper Jaffray | Overweight |
| Mar-02-17 | Initiated | Instinet | Buy |
| Dec-21-16 | Initiated | SunTrust | Buy |
| Nov-03-16 | Initiated | Deutsche Bank | Buy |
| Aug-04-16 | Reiterated | Barclays | Overweight |
| May-13-16 | Initiated | Barclays | Overweight |
| Feb-19-16 | Reiterated | Wedbush | Outperform |
| Jan-21-16 | Initiated | Credit Suisse | Outperform |
View All
Prothena Corporation Plc Stock (PRTA) Latest News
Prothena to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026 - Business Wire
Prothena (PRTA) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Aug Levels: Will Prothena Corporation plc benefit from rising consumer demandMarket Performance Recap & High Accuracy Trade Alerts - baoquankhu1.vn
Volatility Watch: How do insiders feel about Prothena Corporation plcWeekly Stock Report & Smart Money Movement Tracker - baoquankhu1.vn
Prothena Corporation plc (NASDAQ:PRTA) Given Average Rating of "Hold" by Analysts - MarketBeat
How (PRTA) Movements Inform Risk Allocation Models - Stock Traders Daily
Prothena Corporation plc $PRTA Shares Sold by Federated Hermes Inc. - MarketBeat
Prothena Corporation plc (PRTA) Stock Analysis: Exploring a Potential 124% Upside in Biotech Innovations - DirectorsTalk Interviews
Prothena (NASDAQ:PRTA) Share Price Crosses Above 50 Day Moving AverageHere's Why - MarketBeat
Can Calidi Biotherapeutics Inc reach resistance levels soonWeekly Stock Summary & Community Trade Idea Sharing - baoquankhu1.vn
Trading Systems Reacting to (PRTA) Volatility - Stock Traders Daily
Prothena Corporation Plc (PRTA) Stock Analysis: Evaluating A Potential 96.65% Upside - DirectorsTalk Interviews
Will Prothena Corporation plc benefit from rising consumer demand2025 Market Outlook & Daily Profit Focused Stock Screening - mfd.ru
All You Need to Know About Prothena (PRTA) Rating Upgrade to Buy - Yahoo Finance
Aug Sectors: Will Prothena Corporation plc outperform tech stocks2025 EndofYear Setup & Risk Managed Investment Entry Signals - baoquankhu1.vn
Recap Report: Will Melar Acquisition Corp I announce a stock split2025 Price Momentum & Precise Entry and Exit Recommendations - baoquankhu1.vn
Prothena Corporation plc (NASDAQ:PRTA) Sees Significant Growth in Short Interest - MarketBeat
Prothena Corp (PRTA) Analyst Ratings: RBC Capital's New Price Ta - GuruFocus
Prothena announces board of directors update - MSN
How Prothena Corporation Plc (PRTA) Affects Rotational Strategy Timing - Stock Traders Daily
Value Recap: What Wall Street predicts for Prothena Corporation plc stock price2025 Pullback Review & Consistent Income Trade Recommendations - Bộ Nội Vụ
Prothena Corporation plc (NASDAQ:PRTA) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
Prothena Corporation plc (NASDAQ:PRTA) Receives Consensus Rating of “Hold” from Brokerages - Defense World
Can Prothena Corporation plc stock sustain revenue growthJuly 2025 PostEarnings & Entry Point Strategy Guides - Улправда
Why hedge funds are buying Prothena Corporation plc stockDay Trade & Daily Entry Point Trade Alerts - Улправда
How Are Partnered Pipelines Rewriting The Prothena (PRTA) Narrative And Price Target Outlook - Yahoo Finance UK
Macro Review: What valuation multiples suggest for Prothena Corporation plc stockWeekly Profit Summary & Long Hold Capital Preservation Plans - Bộ Nội Vụ
We Think Prothena (NASDAQ:PRTA) Can Afford To Drive Business Growth - Yahoo Finance
(PRTA) and the Role of Price-Sensitive Allocations - Stock Traders Daily
89,704 Shares in Prothena Corporation plc $PRTA Acquired by Assenagon Asset Management S.A. - Defense World
(PRTA) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Prothena Corporation plc(NasdaqGS:PRTA) added to S&P Biotechnology Select Industry Index - marketscreener.com
Squarepoint Ops LLC Takes $1.27 Million Position in Prothena Corporation plc $PRTA - Defense World
Earnings Miss: Why Prothena Corporation plc stock remains undervaluedStock Surge & Fast Entry Momentum Trade Alerts - Улправда
Why Prothena Corporation plc stock remains undervaluedDip Buying & Free High Return Stock Watch Alerts - Улправда
What catalysts could drive Prothena Corporation plc stock higherDip Buying & AI Based Trade Execution Alerts - DonanımHaber
Prothena Corporation plc (NASDAQ:PRTA) Given Average Recommendation of "Hold" by Analysts - MarketBeat
Birchview Capital LP Has $2.74 Million Stock Holdings in Prothena Corporation plc $PRTA - MarketBeat
Prothena Board Member Paula Cobb Resigns - The Globe and Mail
Paula Cobb steps down from Prothena’s board to join Manifold Bio - Investing.com Nigeria
Paula Cobb steps down from Prothena’s board to join Manifold Bio By Investing.com - Investing.com South Africa
[8-K] PROTHENA CORP PUBLIC LTD CO Reports Material Event | PRTA SEC FilingForm 8-K - Stock Titan
Prothena Announces Board of Directors Update - Yahoo Finance
What analysts say about Prothena Corporation plc stockMean Reversion Trades & Free Harness Proven Investment Plans - earlytimes.in
Prothena Corporation plc $PRTA Shares Bought by Federated Hermes Inc. - MarketBeat
Liquidity Mapping Around (PRTA) Price Events - Stock Traders Daily
Prothena (PRTA) price target increased by 10.91% to 20.74 - MSN
Ready to Jump After Recent Trade: Prothena Corporation plc (PRTA) - setenews.com
How the Narrative Surrounding Prothena Is Changing After New Pipeline and Valuation Updates - Yahoo Finance
Prothena (PRTA) Price Target Increased by 10.91% to 20.74 - Nasdaq
Will Prothena Corporation plc stock outperform international peersTrade Entry Summary & Breakout Confirmation Trade Signals - Newser
Prothena Corporation Plc Stock (PRTA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):